As debates continue over the legalization of marijuana, many individuals who have never touched plant-derived cannabinoids (phytocannabinoids) do not realize that their bodies naturally produce endocannabinoids, which play an essential mediating role in various human physiologic systems.
China’s growing economy has proven to be beneficial to many across the country. Some of these benefits include higher living standards, better health and nutrition, and longer life expectancy.
Before the opening bell, top-ranked independent research firm WallStreet Research™ (WSR) announced the release of a Corporate Profile Analyst Report covering ChineseInvestors.com, Inc. (OTCQB: CIIX).
ChineseInvestors.com, Inc. (OTCQB: CIIX), a company in the business of providing Chinese-speaking investors with real-time market analysis, commentary, and educational services, recently announced its goals for 2017, stating that it plans to develop a CBD oil-based pharmaceutical that could help with the major problem of epilepsy in China.
China represents a past civilization that has sprung many surprises over the centuries, and has given us some of our greatest inventions, including the compass, gunpowder, papermaking, and printing. On par with these innovations has been Traditional Chinese Medicine (TCM), which has relied, in part, on herbal remedies (tui na).
A SeeThruEquity report released in February revealed that ChineseInvestors.com, Inc. (OTCQB: CIIX), a specialized investment services company targeting primarily the Chinese-speaking population in the U.S., has made several investments in the global cannabis industry, increasing its growth potential.
A population of over 1.2 billion people is one heck of a target market, especially when insulated by language. ChineseInvestors.com (OTCQB: CIIX) has leveraged this demographic to market a broad range of products, services and information specifically for the Chinese speaking population.
Marijuana use is currently illegal in China, but cannabis-based oils, including hemp-based CBD, are legal, giving CIIX access to a market of almost two billion potential customers in that country.
CBD has long been considered to have a broad range of medical benefits. Now, two major studies released in the last four months have scientifically validated the medicinal efficacy of CBD.
With an annual growth rate of nearly 60 percent, CBD oil has become one of the fastest-growing market categories in the country. U.S.-based ChineseInvestors.com, Inc. (OTCQB: CIIX) is set to capitalize on this meteoric growth.
ChineseInvestors.com, Inc. (OTCQB: CIIX) has been closely monitored for its upside as it competes in the hemp-derived cannabis market. CIIX has launched a cannabidiol (CBD) online store in the free-trade zone of Shanghai and soon it plans to open a brick-and-mortar store in its home market of San Gabriel, California, to market a line of food and nutrition products.
The company operates the first online Chinese language CBD health product store. Now, two billion Chinese can order their medicine online and have it delivered to their homes.
After making a successful investment in the marijuana market, the company recently expanded into the retail and online sale of cannabidiol (CBD), which has become one of the fastest-growing market categories in the United States.
Not satisfied with a 100,000+ user base, a recognizable 18-year-old brand, and a target market in excess of two billion Chinese speaking people, ChineseInvestors.com recently executed a first-to-market milestone by creating the world’s only Chinese language, cannabinoid-based, therapeutic health products online store, http://www.ChineseCBDoil.com.
ChineseInvestors.com, Inc. (OTCQB: CIIX) is projected to reach revenues of $14.8 million by fiscal year 2020, according to a new research report by Consilium Global Research.
